Open Access

Differential urinary proteomics analysis of myocardial infarction using iTRAQ quantification

  • Authors:
    • Lili Zou
    • Xubo Wang
    • Zhengguang Guo
    • Haidan Sun
    • Chen Shao
    • Yehong Yang
    • Wei Sun
  • View Affiliations

  • Published online on: March 26, 2019     https://doi.org/10.3892/mmr.2019.10088
  • Pages: 3972-3988
  • Copyright: © Zou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Myocardial infarction (MI) is a disease characterized by high morbidity and mortality rates. MI biomarkers are frequently used in clinical diagnosis; however, their specificity and sensitivity remain unsatisfactory. Urinary proteome is an easy, efficient and noninvasive source to examine biomarkers associated with various diseases. The present study, to the best of the authors' knowledge, is the first to examine the urinary proteome using the isobaric tags for relative and absolute quantitation (iTRAQ) technology to identify potential diagnostic biomarkers of MI. The urinary proteome was analyzed within 12 h following the first symptoms of early‑onset MI and at day 7 following percutaneous coronary intervention via iTRAQ labeling and two‑dimensional liquid chromatography‑tandem mass spectrometry. Candidate biomarkers were validated by multiple reaction monitoring (MRM) analysis. A total of 233 urinary proteins were differentially expressed. Gene enrichment analysis identified that the urinary proteome in patients with MI was associated with atherosclerosis, abnormal coagulation and abnormal cell metabolism. In total, 12 differentially expressed urinary proteins were validated by MRM analysis, five of which were associated with MI for the first time in the present study. Binary logistic regression analysis suggested that the combination of five urinary proteins (antithrombin‑III, complement C3, α‑1‑acid glycoprotein 1, serotransferrin and cathepsin Z) may be used to diagnose MI with 94% sensitivity and 93% specificity. In addition, the protein expression levels of three proteins were significantly restored to normal levels following surgical treatment. The verified candidate biomarkers may be used for the diagnosis of MI, and for monitoring the disease status and the effects of treatments for MI. The present results may facilitate future clinical applications of the urinary proteome to diagnose MI.
View Figures
View References

Related Articles

Journal Cover

May-2019
Volume 19 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zou L, Wang X, Guo Z, Sun H, Shao C, Yang Y and Sun W: Differential urinary proteomics analysis of myocardial infarction using iTRAQ quantification. Mol Med Rep 19: 3972-3988, 2019
APA
Zou, L., Wang, X., Guo, Z., Sun, H., Shao, C., Yang, Y., & Sun, W. (2019). Differential urinary proteomics analysis of myocardial infarction using iTRAQ quantification. Molecular Medicine Reports, 19, 3972-3988. https://doi.org/10.3892/mmr.2019.10088
MLA
Zou, L., Wang, X., Guo, Z., Sun, H., Shao, C., Yang, Y., Sun, W."Differential urinary proteomics analysis of myocardial infarction using iTRAQ quantification". Molecular Medicine Reports 19.5 (2019): 3972-3988.
Chicago
Zou, L., Wang, X., Guo, Z., Sun, H., Shao, C., Yang, Y., Sun, W."Differential urinary proteomics analysis of myocardial infarction using iTRAQ quantification". Molecular Medicine Reports 19, no. 5 (2019): 3972-3988. https://doi.org/10.3892/mmr.2019.10088